CIPDB › China Industry › Chemicals › Pharmaceutical Intermediate
Chemical and Weight Loss Retatrutide Raw Powder Retatrutide1
Pharmaceutical IntermediateRetatrutidePeptide Retatrutide
Xi'an Sase Biotechnology Co., Ltd
Preview:
Product DescriptionChemical and Weight Loss Retatrutide Raw Powder RetatrutideProduct DescriptionProduct DetailsProduct NameRetatrutideAppearanceWhite powderCAS2381089-83-2MF0MW0Characteristics of Retatrutide (CAS: 2381089-83-2)Retatrutide is a novel, investigational peptide therapeutic with a complex multi-targeted mechanism of action, featuring a meticulously engineered structure optimized for metabolic regulation. The compound appears as a white to off-white lyophilized powder with high solubility in aqueous buffers (≥50 mg/mL at pH 7.4) and stability maintained for 24 months when stored at -20°C in inert conditions. Its molecular architecture incorporates strategic modifications to enhance proteolytic resistance, including non-natural amino acids and stabilized secondary structures, yielding a plasma half-life of 120–150 hours in preclinical models—a critical feature for weekly dosing regimens. Analytical characterization reveals >99% purity by UPLC-MS (C18 column, 215 nm detection), with stringent controls for related peptides (<0.5% each) and residual solvents (<500 ppm ). The molecule demonstrates picomolar affinity for GLP-1, GIP, and glucagon receptors in radioligand binding assays, with biased signaling profiles tailored to optimize metabolic effects while minimizing adverse reactions. Structural validation includes circular dichroism (CD) spectroscopy confirming α-helical content ≥80% and mass spectrometry verifying the 5,812 Da molecular weight. Stability studies under ICH Q1A conditions show degradation <2% after 6 months at 2–8°C in lyophilized form, though aqueous solutions require strict temperature control (2–8°C, ≤72-hour stability).Application&FunctionFunction and Applications of RetatrutideRetatrutide represents a paradigm-shifting approach to metabolic disease therapy as the first single-molecule triple agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. Currently in Phase 3 trials for obesity and type 2 diabetes, it demonstrates unprecedented efficacy in clinical studies—achieving up to 24% body weight reduction at 48 weeks—while maintaining favorable safety profiles with nausea rates ≤15%. The drug's synchronized receptor activation creates a unique "metabolic relay" effect: GLP-1 enhances satiety and glycemic control, GIP potentiates sensitivity and adipose tissue remodeling, while glucagon agonism sustains energy expenditure through hepatic fat oxidation. Beyond metabolic indications, preclinical data suggest potential in NASH (reducing liver fat by ≥60% in animal models) and cardiovascular risk reduction (improving lipid profiles and endothelial function). The optimized pharmacokinetic profile enables convenient weekly subcutaneous administration, with ongoing research exploring monthly depot formulations. Regulatory agencies (FDA/EMA) have granted Fast Track designation based on its transformative potential, though manufacturing requires specialized peptide synthesis (≥30-step SPPS) and rigorous control of oxidative degradation products. As a research tool, Retatrutide provides critical insights into polypharmacology strategies for complex metabolic networks, while its clinical success may redefine standards for obesity pharmacotherapy.Specification
Purchasing Agent
Note: Send your message to supplier or manufacturer.
Welcome to our Professional and comprehensive procurement services...